IP
ANIK icon

Isthmus Partners’s Anika Therapeutics ANIK Stock Holding History

Isthmus Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,009
Closed -$572K – 144
2019
Q1 		$572K Sell
3,009
-19,478
-87% -$667K 0.14% 112
2018
Q4 		$756K Buy
22,487
+3,621
+19% +$131K 0.23% 98
2018
Q3 		$796K Buy
18,866
+534
+3% +$21.1K 0.2% 95
2018
Q2 		$587K Buy
18,332
+1,427
+8% +$58.8K 0.15% 105
2018
Q1 		$841K Buy
16,905
+495
+3% +$28K 0.23% 82
2017
Q4 		$885K Buy
16,410
+89
+0.5% +$4.93K 0.24% 78
2017
Q3 		$947K Buy
16,321
+55
+0.3% +$2.88K 0.27% 69
2017
Q2 		$803K Sell
16,266
-62
-0.4% -$2.85K 0.23% 82
2017
Q1 		$709K Buy
16,328
+337
+2% +$16.1K 0.21% 89
2016
Q4 		$783K Sell
15,991
-285
-2% -$13.2K 0.24% 78
2016
Q3 		$758K Sell
16,276
-12
-0.1% -$593 0.24% 69
2016
Q2 		$874K Sell
16,288
-453
-3% -$21.3K 0.29% 54
2016
Q1 		$749K Sell
16,741
-51
-0.3% -$2.07K 0.25% 63
2015
Q4 		$641K Buy
+16,792
New +$642K 0.22% 79

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Isthmus Partners's ANIK Position: Q2 2019 in Review

Isthmus Partners sold out of Anika Therapeutics (ANIK) in Q2 2019, closing a stake of 3,009 shares — an estimated $572K sold.

Isthmus Partners first reported a position in ANIK in Q4 2015 and held it in 14 quarters. The position peaked at $947K in Q3 2017. 165 funds tracked by Wall St. Rank hold ANIK as of Q2 2019.

  • Isthmus Partners reported no remaining Anika Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Isthmus Partners sold 3,009 Anika Therapeutics shares in Q2 2019, an estimated $572K.
  • Isthmus Partners first reported a position in Anika Therapeutics in Q4 2015 and held it in 14 quarters.
  • Isthmus Partners's Anika Therapeutics position peaked at $947K in Q3 2017.
  • 165 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2019.

Based on Isthmus Partners's 13F filing for Q2 2019, filed 9 Aug 2019.